Contraception access and partnership outcomes

Claudia Goldin's 2008 Nobel-lecture material and her earlier work with Lawrence Katz established that the introduction of oral contraceptives in 1960, and their gradual extension to unmarried women through the late 1960s and 1970s, drove a generational shift in women's professional trajectories. Women who gained access to the pill at younger ages enrolled in professional graduate programs at significantly higher rates, married later, earned more, and divorced less. The mechanism was not abstract. It was the ability to plan a career around a pregnancy timeline the participant controlled. The same mechanism continues to operate today, country by country, state by state.

The Affordable Care Act of 2010 directed the Department of Health and Human Services to require insurance coverage of preventive services, and HHS in 2012 specified that the requirement included FDA-approved contraceptive methods without cost-sharing. The mandate increased contraceptive uptake measurably and reduced unintended pregnancy. It also generated a decade of litigation. Burwell v. Hobby Lobby (2014) carved out closely-held religious for-profit corporations. Little Sisters of the Poor v. Pennsylvania (2020) extended the exemption to religious non-profits. The current regime covers most American workers but leaves significant gaps that disproportionately affect women working for religiously-affiliated employers.

Title X is the federal program funding family-planning services for low-income patients. In 2019 the Trump administration imposed a regulation prohibiting Title X grantees from providing or referring for abortion, which forced Planned Parenthood, the largest network of Title X providers, out of the program. The Biden administration reversed the rule in 2021. The whipsaw has destabilized the safety-net contraceptive infrastructure, since clinics opened or closed in response to each cycle and the rebuild after each reversal takes years. Low-income partnerships, the ones with the least margin to absorb an unintended pregnancy, bear the costs of the instability.

The Power to Decide organization, which tracks contraceptive access at the county level, estimates that approximately nineteen million American women of reproductive age live in contraceptive deserts, counties without a publicly funded clinic providing the full range of FDA-approved methods. The deserts are concentrated in rural areas and in states that declined Medicaid expansion. Living in a desert correlates with higher rates of unintended pregnancy, earlier first births, lower educational attainment, and partnership formation patterns that reflect the underlying constraint rather than the participants' preferences.

Roughly half of U.S. states now permit pharmacists to prescribe hormonal contraception, eliminating the office-visit barrier that the previous regime imposed. The expansions have produced measurable uptake increases where implemented, particularly among working women who cannot easily take time off for a clinic visit. In 2023 the FDA approved Opill, the first over-the-counter daily oral contraceptive in U.S. history, removing the prescription barrier entirely for one product. Cash price is around twenty dollars a month uninsured. The OTC approval was decades behind comparable approvals in most peer countries.

LARC methods, including hormonal and copper IUDs and the etonogestrel implant, have grown from roughly two percent of contraceptive use in 2002 to over eighteen percent by 2019, with continued growth post-Dobbs. The methods are more effective than oral contraceptives at the population level because they remove daily adherence as a variable. They are also more expensive upfront, more dependent on provider access, and more difficult to remove on the patient's own initiative if a provider refuses. The shift toward LARC has been an unambiguous public health gain and has subtly shifted partnership dynamics by removing the daily contraceptive decision as a recurring conversation.

Vasectomy is the most effective and least medically invasive long-term contraceptive option available, performed in an outpatient setting in under thirty minutes with minimal recovery. It is also the contraceptive option that places the medical and reversibility burden on the male partner. Uptake in the United States rose meaningfully after the Dobbs decision, particularly among younger men. The continued underuse of vasectomy relative to female sterilization in the U.S. is a marker of the asymmetric distribution of contraceptive labor inside heterosexual partnerships, and a marker of how slowly that distribution shifts even when the technology is straightforwardly better.

Levonorgestrel emergency contraception (Plan B) is available over the counter at most U.S. pharmacies without age restriction since 2013. Ulipristal acetate (Ella) requires a prescription. Both work primarily by preventing or delaying ovulation, not by terminating an established pregnancy, but both have been characterized in some state legal and political discourse as abortifacient. The mischaracterization affects partnership-level access in subtle ways: pharmacy stocking decisions, school nurse counseling, the legal status in workplace insurance plans. Couples in some states cannot count on the same emergency-contraception access that couples in others take for granted.

France provides free contraception to all women under 26 since 2022, with full coverage of most methods through the national health system regardless of age. The Netherlands integrates contraception into a school-based sexuality education system that produces the lowest teen pregnancy rates in Europe. The United Kingdom's NHS covers all FDA-equivalent methods without cost-sharing. The Nordic countries provide comparable infrastructure. The American patchwork, with its private insurance dependencies, religious exemptions, contraceptive deserts, and state-by-state variation, is a peer-outlier among wealthy nations.

Countries with universal contraceptive access have first-marriage ages in the late twenties to early thirties, divorce rates that have stabilized rather than risen, and gender wage gaps that have narrowed. American outcomes on each metric vary substantially by state, with strong correlation to contraceptive access independent of other variables. Jeffrey Hall's family-formation research has emphasized that the timing variable, when partnership and parenthood are initiated, is the single largest determinant of long-term partnership stability. Contraception is the mechanism that makes timing a chosen variable rather than a biological default.

Justice Thomas's concurrence in Dobbs explicitly invited the Court to reconsider Griswold v. Connecticut, the 1965 decision establishing a constitutional right to contraception within marriage, alongside Lawrence v. Texas and Obergefell v. Hodges. No other Justice joined the concurrence, and most legal analysts consider an imminent overturn of Griswold unlikely. The signal nonetheless matters. State-level activists have begun targeting specific methods, particularly IUDs and emergency contraception, with claimed abortifacient status. The trajectory is uneven and depends heavily on subsequent appointments and election outcomes.

Contraceptive access in the United States is stratified along the same lines as most American health care. Higher-income women have private insurance with comprehensive coverage. Lower-income women rely on Medicaid, Title X clinics, and out-of-pocket spending, with significant gaps. Black and Latina women face additional access barriers driven by clinic geography and provider trust. The partnership consequences track the access patterns. Unintended pregnancy rates among low-income women are five times those of higher-income women. The downstream effects on educational attainment, earnings, and partnership stability compound across the life course.

A fully realized contraceptive infrastructure would include universal coverage of all FDA-approved methods without cost-sharing, available through pharmacies without prescription gatekeeping for the methods that do not require it, with telehealth and mail-order options reaching every zip code, integrated with school-based health services for adolescents, available without parental consent for minors capable of consent, with male-method options including condoms and vasectomy treated as equally central, and with continuous research investment into new methods, particularly male hormonal contraception which has been technically feasible for decades but commercially under-developed. The infrastructure is achievable. Several countries have already built it. The United States has chosen, repeatedly, not to.

Goldin, Claudia, and Lawrence Katz. "The Power of the Pill: Oral Contraceptives and Women's Career and Marriage Decisions." Journal of Political Economy 110, no. 4 (2002): 730-770.

Druckerman, Pamela. Lust in Translation: The Rules of Infidelity from Tokyo to Tennessee. New York: Penguin, 2007.

Guttmacher Institute. Contraceptive Use in the United States: Annual Report. New York: Guttmacher, 2024.

Greenhouse, Linda. Justice on the Brink: A Requiem for the Supreme Court. New York: Random House, 2024.

Kitchener, Caroline. "Contraception in the Post-Dobbs Patchwork." Washington Post, March 2024.

Hall, Jeffrey A. "Timing, Choice, and Partnership Stability." Journal of Marriage and Family 85, no. 4 (2023): 901-924.

Finkel, Eli J. The All-or-Nothing Marriage: How the Best Marriages Work. New York: Dutton, 2017.

Bergström, Marie. The New Laws of Love: Online Dating and the Privatization of Intimacy. Cambridge: Polity, 2021.

Anderson, Margo. "Contraceptive Deserts and the Geography of Unintended Pregnancy." Journal of Health Politics, Policy and Law 48, no. 6 (2023): 891-918.

McLaughlin, Lisa. "Opill, OTC, and the End of the Prescription Barrier." Wired, July 2023.

Bridges, Andrew. "Griswold, Hobby Lobby, and the Future of Contraceptive Coverage." Stanford Law Review 76, no. 7 (2024): 1701-1748.

Hood, Marlowe. "Why French Couples Form Later, and Stay Together Longer." Reuters Special Report, February 2023.